{"organizations": [], "uuid": "39fb1c8756fd219c20dc35976e4df6281c64a6b4", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-heron-therapeutics-says-enrollment/brief-heron-therapeutics-says-enrollment-complete-in-both-pivotal-phase-3-studies-for-htx-011-idUSFWN1P30M0", "country": "US", "domain_rank": 408, "title": "BRIEF-Heron Therapeutics Says Enrollment Complete In Both Pivotal Phase 3 Studies For Htx-011", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.723, "site_type": "news", "published": "2018-01-08T21:57:00.000+02:00", "replies_count": 0, "uuid": "39fb1c8756fd219c20dc35976e4df6281c64a6b4"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-heron-therapeutics-says-enrollment/brief-heron-therapeutics-says-enrollment-complete-in-both-pivotal-phase-3-studies-for-htx-011-idUSFWN1P30M0", "ord_in_thread": 0, "title": "BRIEF-Heron Therapeutics Says Enrollment Complete In Both Pivotal Phase 3 Studies For Htx-011", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-heron therapeutics says enrollment complete in both pivotal phase", "sentiment": "negative"}, {"name": "heron therapeutics inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Heron Therapeutics Inc:\n* HERON THERAPEUTICS - ENROLLMENT COMPLETE IN BOTH PIVOTAL PHASE 3 STUDIES FOR HTX-011; TOP-LINE RESULTS EXPECTED IN H1 OF 2018\n* HERON THERAPEUTICS INC - FOR PHASE 3 EFFICACY STUDIES IN BUNIONECTOMY AND HERNIA REPAIR, EXPECTS TO FILE AN NDA WITH FDA IN H2 OF 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T21:57:00.000+02:00", "crawled": "2018-01-09T17:05:23.027+02:00", "highlightTitle": ""}